Imaging Biometrics Ltd (IBAI) RNS Announcements

Add to Alert list
Date Time Source Announcement
22 Jan 2024 10:05 AM
RNS
Holding(s) in Company
15 Jan 2024 07:01 AM
RNS
Director Dealings and Conversion of CLNs
15 Jan 2024 07:00 AM
RNS
Holding(s) in Company
10 Jan 2024 07:00 AM
RNS
IB Launching an Expanded Access Program for GaM
19 Dec 2023 02:29 PM
RNS
Imaging Biometrics granted FDA “Fast-Track”
05 Dec 2023 10:58 AM
RNS
IQ-AI Announces Positive Interim Phase 1 Results
20 Nov 2023 01:42 PM
RNS
Holding(s) in Company
09 Nov 2023 11:38 AM
RNS
Director Dealing and Conversion of CLNs
08 Nov 2023 10:59 AM
RNS
Application for Pediatric Rare Disease Designation
06 Nov 2023 01:02 PM
RNS
Holding(s) in Company
18 Oct 2023 02:29 PM
RNS
Update Regarding Imaging Biometrics LLC
13 Oct 2023 08:55 AM
RNS
IB Letter to Shareholders
09 Oct 2023 07:00 AM
RNS
Orphan Drug Status to GaM and Total Voting Rights
03 Oct 2023 11:30 AM
RNS
Holding(s) in Company
19 Sep 2023 02:32 PM
RNS
IQ-AI shares cease trading on the OTCQB
08 Sep 2023 07:00 AM
RNS
Reduced Gadolinium Approach Validated'
18 Aug 2023 12:06 PM
RNS
Update on Collaboration Agreement with Mayo Clinic
18 Aug 2023 11:20 AM
RNS
IB & GE HealthCare Enter into Commercial Agreement
17 Aug 2023 07:00 AM
RNS
Half-year Report
19 Jul 2023 07:00 AM
RNS
Imaging Biometrics Installs IB Nimble™ For MCW
13 Jul 2023 07:00 AM
RNS
Orphan Drug Designation for GaM in Pediatric GBM
27 Jun 2023 07:00 AM
RNS
Studies Show GaM Inhibits Pediatric Tumor Growth
23 May 2023 11:02 AM
RNS
Result of AGM
23 May 2023 07:00 AM
RNS
AGM Statement
03 May 2023 04:14 PM
RNS
Notice of AGM
26 Apr 2023 07:00 AM
RNS
Final Results
28 Feb 2023 03:52 PM
RNS
Orphan Drug Designation Status
13 Jan 2023 02:05 PM
RNS
Second Price Monitoring Extn
13 Jan 2023 02:00 PM
RNS
Price Monitoring Extension
13 Jan 2023 11:05 AM
RNS
Second Price Monitoring Extn
13 Jan 2023 11:00 AM
RNS
Price Monitoring Extension
10 Jan 2023 07:00 AM
RNS
Letter to Shareholders
02 Dec 2022 11:11 AM
RNS
Holding in Company
25 Oct 2022 11:00 AM
RNS
Price Monitoring Extension
30 Sep 2022 07:00 AM
RNS
Letter to Shareholders
26 Sep 2022 07:00 AM
RNS
Issue of Warrants to Employees
16 Aug 2022 04:40 PM
RNS
Second Price Monitoring Extn
16 Aug 2022 04:35 PM
RNS
Price Monitoring Extension
16 Aug 2022 09:28 AM
RNS
Half-year Report
03 Aug 2022 01:01 PM
RNS
TR1 - Notification of Major Holdings
11 Jul 2022 07:00 AM
RNS
Imaging Biometrics Announces Channel Partnership
31 May 2022 11:05 AM
RNS
Second Price Monitoring Extn
31 May 2022 11:00 AM
RNS
Price Monitoring Extension
31 May 2022 08:00 AM
RNS
Submission of FDA 510(k) Application for IB Zero G
30 May 2022 10:47 AM
RNS
Result of AGM
05 May 2022 03:00 PM
RNS
Notice of AGM
03 May 2022 02:21 PM
RNS
IB Broadens Quantitative Mapping
28 Apr 2022 05:52 PM
RNS
Final Results
09 Mar 2022 03:08 PM
RNS
IQAI's Sponsored Phase I Clinical Trial is Open
28 Feb 2022 11:12 AM
RNS
Total Voting Rights

IQ-AI Ltd operates as an investment company. The principal activity of the group is the provision of convenient, cost-effective, and clinical treatments to patients in the field of medical imaging diagnostics, based on proven technologies. Its geographical segment includes Jersey and the United States of America and reportable segments are holding company expenses and medical software. The company derives a majority of revenue from the United States of America. It also supplies medical technology solutions and has a strong neuroimaging product portfolio.

IQ-AI share price listed in London at 87p in 1996.

UK 100

Latest directors dealings